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Histone deacetylase inhibitors (HDACi) were identified nearly four decades ago based on their ability to induce cellular differenti-
ation. However, the clinical development of these compounds as cancer therapies has focused on their capacity to induce apoptosis
in hematologic and lymphoid malignancies, often in combination with conventional cytotoxic agents. In many cases, HDACi
doses necessary to induce these effects result in significant toxicity. Since osteosarcoma cells express markers of terminal osteoblast
differentiation in response toDNAmethyltransferase inhibitors, we reasoned that the epigenetic reprogramming capacity ofHDACi
might be exploited for therapeutic benefit. Here, we show that continuous exposure of osteosarcoma cells to low concentrations of
HDACi LBH589 (Panobinostat) over a three-week period induces terminal osteoblast differentiation and irreversible senescence
without inducing cell death. Remarkably, transcriptional profiling revealed that HDACi therapy initiated gene signatures
characteristic of chondrocyte and adipocyte lineages in addition to marked upregulation of mature osteoblast markers. In a mouse
xenograftmodel, continuous lowdose treatmentwith LBH589 induced a sustained cytostatic response accompanied by induction of
mature osteoblast gene expression.These data suggest that the remarkable capacity of osteosarcoma cells to differentiate in response
to HDACi therapy could be exploited for therapeutic benefit without inducing systemic toxicity.
1. Introduction
Osteosarcoma is a malignant mesenchymal neoplasm char-
acterized by primitive osteoblastic cells [1] that represents
the most prevalent primary tumour of bone, mainly arising
in adolescents and in adults over the age of 50 [2]. Despite
advances in surgical techniques and neoadjuvant chemother-
apy, it remains the second leading cause of cancer-related
death in children and young adults, and it contributes signif-
icantly to the health care burden of our society [3]. Approx-
imately 20% of patients present with metastases and of the
remaining 80%; a further 25%–50% will develop metastatic
disease during their treatment [4, 5]. The use of adjuvant
chemotherapy in osteosarcoma has significantly increased
the 5-year survival rate from 10% to 70% for nonmetastatic
disease [6]. However, cure rates for patients with metastatic
or relapsed disease are poor, with a 5-year survival rate of
<20% [7, 8]. The stagnation of these survival rates since the
introduction of adjuvant chemotherapy three decades ago
highlights the urgent need for new and improved therapeutic
approaches to treat this disease.
Epigenetics is defined as a heritable change in gene
expression without alteration of the underlying genetic
sequence [9]. Epigenetic gene silencing is a critical modulator
of key mammalian biological processes during development
and has emerged as a central component of most cancers.
2 Sarcoma
Chromatin remodeling represents a major epigenetic mech-
anism of gene transcriptional regulation and is dependent
on the posttranscriptional modification of histone proteins.
Histone acetylation by histone acetyltransferases (HAT)
results in the loosening of chromatin allowing replication and
transcription, whereas deacetylation by histone deacetylases
(HDAC) results in condensation of chromatin and tran-
scriptional silencing. Deregulation of the intricate balance of
these opposing functions is associated with different human
diseases, including cancer.
Histone deacetylase inhibitors (HDACis) are an emerging
class of anticancer agents. HDACis preferentially alter the
acetylation profile of both histone and nonhistone proteins in
tumor cells leading to changes in gene expression, induction
of apoptosis, and cell cycle arrest [10]. Whilst HDACi were
originally discovered by their ability to induce erythroid dif-
ferentiation of erythroleukemia cells [11, 12], the subsequent
use of HDACi in cancer therapy has concentrated on its func-
tions as a cytotoxic agent. The US Food and Drug Adminis-
tration approval of the HDACi’s vorinostat and romidepsin
in 2006 and 2009, respectively, for the treatment of refractory
cutaneous T-cell lymphoma has paved the way for the intro-
duction of at least 10 other HDACis in human clinical trials
[13]. While these studies demonstrate single-agent activity of
HDACi in hematological malignancies, the effectiveness of
HDACi in solid malignancies has been underwhelming [13].
Moreover, the significant toxicities associated with achieving
a cytotoxic-related tumour response, particularly in solid
tumours, is a major cause for concern [13].
Evidence that small molecules could induce epigenetic
reprogramming was first described in mesenchymal stem
cells, where the demethylating agent 5-Azacytidine induces
terminal myoblast differentiation due to expression of the
bHLH transcription factor MyoD [14]. Since similar effects
have been observed in response to DNA demethylating
agents in osteosarcoma cells in vitro [15], we determined
whether HDACi had the capacity to act as a differentiation
agent rather than a cytotoxic agent in osteosarcoma.
2. Materials and Methods
2.1. Cell Culture. Authenticated B143, MG-63, Saos-2, SJSA,
and U2OS human osteosarcoma cell lines were obtained
from ATCC and maintained in DMEM (Gibco, Invitrogen)
supplemented 10% FCS, 100U/mL penicillin, and 10mg/mL
streptomycin in a humidified 5% CO
2
/95% air atmosphere at
37∘C.
2.2. Compounds. LBH589was provided byNovartis Pharma-
ceuticals (Basel, Switzerland). For in vitro and in vivo stud-
ies, LBH589 was reconstituted in DMSO and 5% dextrose,
respectively, according to manufacturer’s instructions.
2.3. Cell Viability. Cells (2 × 103) were plated in 96 wells,
allowed to adhere for 4 hrs, then treated for 96 hrs with
increasing concentrations of LBH589 or DMSO vehicles. Rel-
ative viable cell number was determined using a bioreductive
fluorometric assay (alamarBlue, Life Technologies, Invitro-
gen) according to manufacturer’s directions. Fluorescence
was determined after 6hrs using a microplate reader (FLU-
OROstar OPTIMA, BMG Labtech) set to 560 excitation/590
emission settings. Cell viability wasmeasured at 0, 24, 48, and
96 hrs. Following each analysis, media containing residual
alamarBlue reagent was removed and replaced with fresh
treatment media allowing for repeated measurement of the
same wells over the culture period.
2.4. Analysis of Cell Cycle and Apoptosis by Flow Cytometry.
Following 48 hrs culture in DMSO vehicle, 15 nM LBH589,
or 200 nM LBH589, adherent and supernatant cells were
harvested, washed twice with PBS and fixed in 70% ethanol
at −20∘C. Cells were then washed twice with PBS, and resus-
pended at a density of 1×106 cells/mL in 20𝜇g/mLpropidium
iodide/0/1% Triton X-100 staining solution with 2.5𝜇g/mL
RNase A. Cell cycle distribution was determined using the
BD Biosciences FACSCanto II Analyzer. At least 20,000 cells
were collected. The cell cycle profiles were determined using
FlowJo software (version 7.6.3). For analysis of apoptosis,
adherent and supernatant cells were harvested, washed twice
in PBS, and resuspended in 1x binding buffer at a density of
1×10
6 cells/mL. FITCAnnexinV (BDPharmingen) and pro-
pidium iodide at a final concentration of 50𝜇g/mLwas added
to 1 × 105 cells, gently vortexed, and incubated at room tem-
perature in the dark for 15mins. FITC Annexin V positive
cells were analyzed using the BD Biosciences FACSCanto II
Analyzer within 1 hr.
2.5. Qualitative and Quantitative Analysis of Differentiation.
Cells (1 × 104) were plated in 6-well plates, allowed to adhere
overnight, and treated with 15 nM LBH589 or DMSO vehicle
for 21 days. Media were changed every 3 days, and cells were
split at 80% confluence. For qualitative analysis of osteoblast,
adipocyte, and chondrocyte differentiations, cultures were
washed in PBS, fixed in 10% buffered formalin, rinsed with
dH
2
O, and stained in Alizarin Red (Sigma, 2%, pH 4.1), Oil
Red O (Sigma), and Alcian Blue (Sigma), respectively. For
quantitative analysis of osteoblast differentiation, RNA was
prepared using RNeasyMini Kits (QIAGEN) and cDNA gen-
erated using first-strand cDNA synthesis (Invitrogen) from
total RNA. Real-time PCRwas carried out using SYBRGreen
(Applied Biosystems) according to manufacturers instruc-
tions using an ABI-Prism 7000 Sequence Detection System.
All primers sequences are listed in Supplemental Table 1 in
Supplementary Material available online at http://dx.doi.org/
10.1155/2013/608964.
2.6. Senescence 𝛽-Galactosidase Staining. Following 21 days
cultured cells were rinsed in PBS, fixed in lacZ fix solution
(0.2% glutaraldehyde, 2% buffered formalin), washed in
PBS, and incubated in staining solution (1mg/mL X-gal,
potassium ferrocyanide, and potassium ferricyanide) at 37∘C
overnight in the dark.
2.7. Protein Acetylation. Cells (1 × 106) were plated in T25
flasks, allowed to adhere overnight and treated with 5, 10, 20,
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50, 100, and 200 nM LBH589 or DMSO vehicle for 24 hrs.
Cells were collected and centrifuged at 1000 rpm for 5mins,
washed in PBS, centrifuged as before, and resuspended in
100 uL of RIPA lysis buffer including protease inhibitors. Cells
were incubated on ice for 30mins, centrifuged at 15,000 rpm
for 15mins at 4∘C, and the supernatant was collected in a
clean tube. Protein acetylation was determined by western
blot analysis on whole cell extracts, separated on a 4–12%
Tris-Bis gel (Invitrogen), and transferred to nitrocellulose
membrane (Perkin-Elmer). Blots were stained with anti-
rabbit Acetyl-Histone H3 (Cell Signalling, no.9675)), anti-
rabbit Acetyl-Histone H4 (Millipore, no. 06-598), anti-rabbit
Acetyl-𝛼-Tubulin (Cell Signalling, no. 5335), anti-rabbit
Acetyl-p53 (Cell Signalling, no.2570S), and anti-mouse Actin
(Abcam, ab3280) and visualized using the Odessey Infrared
Imaging System (v3.0, LI-COR).
2.8. Clonogenic Assay. Following 21 days culture in 15 nM
LBH589 or DMSO vehicle, 1000 cells were plated into 0.7%
Noble agar (Becton, Dickinson and Company) in DMEM
supplementedwith 10%FCS, 100U/mL penicillin, and 10mg/
mL streptomycin, atop of a 1% Noble Agar layer in a 35mm
culture plate. Normal growth media were added on top of
the 0.7% agar layer once set and incubated for 28 days in
a humidified 5% CO
2
/95% air atmosphere at 37∘C. The top
growthmedia were replaced every 3-4 days. At completion of
the culture period, colonies were stained with 0.005% crystal
violet, and colonies>500𝜇mwere counted under a dissecting
microscope. Experiments were performed in triplicate.
2.9. Global Gene Expression Analysis. U2OS, SJSA, and B143
cells were collected from T25 flasks following 21 days culture
in the presence of 15 nM LBH589 or DMSO vehicle. Cultures
were performed in triplicate. RNA from cells was isolated
using the RNeasy Mini Kit (QIAGEN) and snap frozen.
Microarray analysis of RNA were performed by the Australia
Genome Research Facility (Melbourne, Australia) using the
HumanHT-12 v4 Expression BeadChip (Illumina), which
contains 47,231 probes representing over 20,000 genes. Image
processing and probe quantification was performed using the
GenomeStudio software package (version 2011.1, Illumina,
Inc., San Diego, CA, USA). Background correction was
performed by subtracting the average value of the signals of
built-in array negative controls, and background-corrected
probe intensities were normalized using the cubic spline
method. Normalized probe intensities were imported into
Partek Genomics Suite (6th ed. Partek Inc. St. Louis, MO,
USA) for differential gene expression and gene ontology
analyses. An ANOVA test was performed and orthogonal
contrasts were generated to compare different experimental
groups (2-fold change; false discovery rate cutoff 0.05; step-
up procedure [16]; 𝑃 < 0.001). Gene ontology analysis was
performed on the differentially expressed (1.2-fold change;
false discovery rate cutoff 0.05; step-up procedure [16]; 𝑃 <
0.001) of the U2OS cell line. Enriched genes for each of the
assessed functional groups were determined by comparing
the ratios of statistically significant differentially expressed
genes in a functional group over all significant differentially
expressed genes versus all genes in the functional group over
all genes in the microarray chip (Fisher’s exact test).
2.10. HumanOsteosarcomaXenograftModel. Female BALB/c
nude mice (Animal Resources Centre, Australia), 6–8 weeks
of age, received right flank injections of 1 × 106U2OS
cells/mouse in 200 𝜇L of 1 : 1 mixed cell suspension and
Matrigel. Tumour size was measured using digital calipers,
and volumes were calculated according to the formula:
Tumour volume (mm3) = (Width2 × Length)/2. Once
tumours reached a volume of 100mm3, animals were ran-
domized to receive daily intraperitoneal injections of vehicle
control (5% dextrose) or 2mg/kg, 5mg/kg, or 10mg/kg
LBH589. Mouse body weight and tumour volumes were
measured daily. Experiments were terminated upon a ≥10%
reduction in bodyweight; tumour size exceeded 10mm in any
axis, or after 17 days treatment. All experiments involving
animals were approved in advance by an Animal Ethics
Committee at Monash University and were carried out in
accordance with “Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes.”
2.11. Statistics. Statistical analysis was performed using
GraphPad Prism software (version 5.0c). Data were analyzed
using 2-tailed Student’s 𝑡 test. A probability of less that 0.05
was considered to indicate statistical significance.
3. Results
3.1. LBH589 Inhibits Human Osteosarcoma Cell Growth. To
investigate the effect of LBH589 in osteosarcoma, we cultured
a panel of 5 human osteosarcoma cell lines (U2OS, SJSA,
Saso2, MG-63, and B143) in the presence of increasing con-
centrations of LBH589 (0.5–500 nM). Assessment of cell via-
bility using alamarBlue demonstrated a significant reduction
in cell growth of all cell lines following 96 hours of continuous
exposure with an IC
50
of approximately 6, 8, 3, 22, and 8 nM,
respectively, (Figures 1(a) and 1(b), Supplementary Figure 1).
Specifically, LBH589 concentrations <15 nM resulted in a
marked reduction in cell growth, 15–30 nM caused a growth
arrest, and >30 nM led to cell death as observed morpho-
logically by cell rounding and detachment (Supplementary
Figure 2A). Despite reduced cellular growth, no cell death
was observed below 30 nM. Cell cycle analysis following 48
hours exposure toDMSO control, low-dose LBH589 (15 nM),
and high-dose LBH589 (200 nM) demonstrated an accumu-
lation of cells in G0/G1 (43% versus 48% and 70% resp.) and
a reduced proportion of cells in S-phase (31% versus 24%
and 12% resp.) consistent with reduced cellular growth and
arrest (Supplementary Figure 2B). Analysis of apoptosis by
Annexin V staining in these samples revealed a similar pro-
portion of early apoptotic cells in DMSO (5%) and low-dose
LBH589-treated (7%) cells but a marked increase in high-
dose LBH589-treated (23%) cultures consistent with our
morphological observations (Supplementary Figure 2C). To
assess the effects of LBH589 on acetylation of histone pro-
teins, the human osteosarcoma cell lines were cultured for
24 hours in the presence of increasing concentrations of
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Figure 1: LBH589 inhibits cell growth and drives osteoblast differentiation of U2OS human osteosarcoma cells. (a) Survival curve of human
osteosarcoma cell lines treated with increasing concentrations of LBH589. Data represent means ± SEM of quadruplicates. (b) Cell viability
of U2OS cells treated with increasing concentrations of LBH589. Data represent means ± SEM of quadruplicates and dotted line = starting
cell number. (c) Western blot analysis of U2OS cells with increasing concentrations of LBH589 for 24 hours. (d) Analysis of cell morphology,
mineralized extracellular matrix deposition, and cellular senescence in U2OS cells treated for 21 days in 15 nM LBH589 by phase contrast
microscopy, Alizarin red staining, and 𝛽-galactosidase staining, respectively. Scale bar = 500 𝜇m. (e) Soft agar clonogenicity assay of U2OS
and SJSA human osteosarcoma cells pretreated with 15 nM LBH589 for 21 days. Mean ± SEM, ∗𝑃 < 0.05, and ∗∗𝑃 < 0.01.
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LBH589 (5–200 nM). All cell lines demonstrated a progres-
sive increase in histones H3 and histone H4 acetylation with
increasing concentrations of LBH589 (Figure 1(c), Supple-
mentary Figure 1). Similarly, acetylation of the nonhistone
protein, 𝛼-Tubulin, also increased with increasing LBH589
concentrations (Figure 1(c), Supplementary Figure 1). Inter-
estingly, acetylation of another nonhistone protein, P53, was
only observed at high LBH589 concentrations associatedwith
cell death (Figure 1(c)). Notably, the most dramatic increase
in Histone protein acetylation occurred between 10 and
20 nM of LBH589, corresponding to the concentrations that
elicit the most pronounced growth inhibition in the absence
of cell death. Since there is also no detectable P53 acetylation
at this range, we selected 15 nM to further investigate the
mechanisms of action of a low-dose, sublethal concentration
of LBH589 in osteosarcoma cells.
3.2. Low-Dose LBH589 Induces Differentiation and Senescence
of Human Osteosarcoma Cells. We investigated the conse-
quence of sustained growth inhibition and arrest caused by
continuous treatment of human osteosarcoma cell lines with
15 nM LBH589 over a 21-day culture period. Inhibition of
osteosarcoma cell growth was preceded by an almost com-
plete growth arrest in the U2OS, SJSA, Saos-2, and MG-63
cell lines after approximately 7 days of culture accompanied
by a progressive change in cell morphology. In contrast to
the small, spindle-shaped cells in DMSO control cultures,
cells treatedwith 15 nMLBH589were significantly largerwith
large extracellular projections (Figure 1(d), Supplementary
Figure 1). These cells remained viable over the remaining
duration of the culture period. To determine whether
LBH589-mediated growth inhibition was irreversible, we
washed out LBH589 and replaced with normal growth
medium at daily intervals (Supplementary Figure 3). Whilst
U2OS cells pretreated for 1–6 days with 15 nM LBH589
resumed a growth rate similar to DMSO controls, cells
cultured for ≥7 days demonstrated a sustained growth
inhibition following LBH589 withdrawal (Supplementary
Figure 3). The dramatic growth arrest and distinct morphol-
ogy of LBH589-treated cells suggested they had undergone
terminal differentiation and/or cellular senescence. Since,
osteosarcoma cells undergo osteoblast differentiation when
cultured in osteogenic culture media [15], we investigated
the possibility of low-dose LBH589 alone inducing osteoblast
differentiation. In accord with this, cells treated with 15 nM
LBH589 for 21 days stained positively with a marker of
mineralized extracellular matrix, Alizarin Red (Figure 1(d)).
Low-dose LBH589 also induced senescence of osteosarcoma
cells as evidenced by 𝛽-galactosidase staining following 21
days treatment (Figure 1(d)).
We reasoned that cell differentiation and senescence are at
the expense of osteosarcoma cell self-renewal. Indeed, colony
numbers of U2OS (101.3 ± 14.7 versus 32.0 ± 5.0, 𝑛 = 3, 𝑃 <
0.05) and SJSA (273.0 ± 11.0 versus 70.0 ± 7.0, 𝑛 = 3, 𝑃 < 0.01)
cells were significantly reduced in soft agar following 15 nM
LBH589 treatment for 21 days (Figure 1(e)). These results
demonstrate that low-dose LBH589 reduces osteosarcoma
cell clonogenicity by inducing senescence and differentiation
of human osteosarcoma-initiating cells.
3.3. Low-Dose LBH589 Treatment of Osteosarcoma Cells
Induces Changes in Relevant Gene Expression Profiles. To
assess LBH589-induced changes in global mRNA expression
changes, we performed genome-wide transcriptional profil-
ing of U2OS, SJSA, and B143 cells following 21 days of con-
tinuous treatment with 15 nM LBH589. Principle component
analysis of microarray data revealed a low level of variability
among biological replicates and a marked separation of the
control and LBH589 treatment groups for each cell line
(Figure 2(a)). Further analysis of the U2OS, SJSA, and B143
microarray data by hierarchical cluster analysis also con-
firmed low variability (Figure 2(b)) and identified 1055 (337
downregulated and 718 upregulated), 1103 (336 downregu-
lated and 767 upregulated) and 1711 (599 downregulated and
1112 upregulated) differentially expressed genes between
DMSO control and 15 nM LBH589-treated cells, respectively
(Supplementary Tables 2, 3, and 4).
A gene ontology analysis of the U2OS data performed to
identify functional groups of differentially expressed genes
(Supplementary Table 5) revealed genes involved in cell cycle
regulation and differentiation, including osteogenesis (Fig-
ures 2(c) and 3). Inspection of osteogenesis-related functional
groups for genes that have a functional requirement during
osteoblast differentiation and are downregulated following
LBH589 treatment identified genes associated with prolifer-
ation of osteoprogenitors (FGF2), suppression of osteoblast
differentiation (OSR1), and negative regulation of bone devel-
opment (FGFR3). In contrast, genes upregulated following
LBH589 treatment included markers of osteoblast differenti-
ation (RUNX2, ALPL, BMP4, and SPP1), positive regulators
of skeletal and bone development or ossification (TWSG1,
SMAD3, TP63, and BMP2), and genes expressed by mature
osteoblasts (IL6, LRP5, and CDH11) (Figure 2(c)). To validate
upregulation of osteogenesis-related genes, quantitative real-
time PCR for a panel of known osteoblast differentiation
makers revealed a significant increase in markers of the
osteoblast precursor RUNX2 (3.2 fold ± 0.9, 𝑃 < 0.05),
preosteoblasts COL1A1 (6.5 fold ± 2.2, 𝑃 < 0.05), BMP4 (14.8
fold ± 0.8, 𝑃 < 0.001), ALPL (16.0 fold ± 5.9, 𝑃 < 0.05),
EBF2 (28.2 fold ± 8.5, 𝑃 < 0.01), and mature osteoblasts
BGLAP/osteocalcin (2.3 fold± 0.5,𝑃 < 0.05) and SPP1/osteo-
pontin (42.5 fold ± 16.0, 𝑃 < 0.05) (Figure 2(d)). Taken
together these results suggest that low-dose LBH589 drives
osteoblast differentiation of human osteosarcoma cells.
3.4. Differentiation of Alternative Mesenchymal Lineages Is
Induced by LBH589. Other functional groups enriched by the
gene ontology analysis included the alternative mesenchymal
lineage pathways, chondrogenesis, and adipogenesis. Similar
to the osteogenesis-related functional group, genes that were
downregulated in the LBH589 group were associated with
the negative regulation of chondrogenesis or adipogenesis,
while genes that were upregulated strongly associated with
positive regulation of these processes (Figure 2(c)). To further
explore this, we stained 21-day cultured cells with Alcian Blue
or Oil Red O, markers of cartilage extracellular matrix and
lipid droplets, respectively (Figure 2(e)). Alcian Blue positive
staining was observed in LBH589-treated cells but was com-
pletely absent inDMSOcontrol-treated cultures, indicative of
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Figure 2: Microarray analysis of human osteosarcoma cell lines. (a) Principle component analysis (PCA). Three PCA coordinates describe
56% of the total data variation (PC1, 8.8%; PC2, 18.1%; PC3, 29.1%). Red, B143; blue, SJSA; green, U2OS. (b) Unsupervised hierarchical cluster
analysis. Heatmap representation of differentially expressed genes in U2OS, SJSA, and B143 cells treated for 21 days with 15 nM LBH589 or
DMSO. Each column represents a distinct sample, and each row represents an individual gene. Level of expression is denoted by colour
(blue, low; red, high). (c) Heatmap representation of genes enriched in functional groups associated with osteogenesis, chondrogenesis, and
adipogenesis. Each column represents a distinct sample. (d) Quantitative real-time PCR of U2OS cells cultured for 21 days in the presence of
15 nM LBH589 for expression of osteoblast differentiation markers. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001. (e) Analysis of chondrocyte
and adipocyte differentiations of human osteosarcoma cells treated for 21 days in 15 nM LBH589 by Alcian Blue staining, a marker of cartilage
extracellular matrix, phase contrast microscopy, and the triglyceride marker, Oil Red O. Scale bar = 250 𝜇m.
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terminal chondrocyte differentiation (Figure 2(e)). Similarly,
the presence of intracellular lipid droplets was confirmed in
15 nM LBH589 but not in DMSO control-treated cells by
phase microscopy and positive Oil Red O staining, demon-
strating terminal adipocyte differentiation (Figure 2(e)).
These data are consistent with the possibility that the uncom-
mitted mesenchymal progenitors are the cell of origin for
osteosarcoma and further support the differentiation capabil-
ities of low-dose LBH589.
3.5. LBH589 Induces Cell Cycle Arrest and Senescence of
Human Osteosarcoma Cells. The marked enrichment of
functional groups associated with cell cycle regulation in
our array data prompted us to explore this in more detail.
Expression of proliferation markers KI67 and PCNA were
reduced following LBH589 treatment consistent with cell
growth inhibition and arrest. Notably, genes required forG1/S
transition were overrepresented in our array data, including
CDKN1A, CCND1, CDK2, CDK4, MCM5, CDC2, CDC25A,
and CDC25C (Figure 3) suggesting a cell cycle arrest in the
G0/G1 phase. This gene expression profile is consistent with
the cell cycle analysis following 48 hours of continuous
LBH589 treatment demonstrating an increased proportion
of cells in G0/G1 and reduced proportion of cells is S-phase
(Supplementary Figure 2). G1 phase growth arrest and
changes in cellular morphology are consistent with terminal
cell differentiation [17] and/or cell senescence and also cor-
roborate our data described above. Furthermore, our array
results demonstrated an increase in genes associated with the
secretory-associated senescence phenotype (SASP) (Figure 3).
These results suggest that both cellular differentiation
and senescence are features of low-dose LBH589-mediated
growth arrest. Interestingly, whilst the P53 transcriptional
target, CDKN1A, was upregulated >3-fold in the LBH589-
treated cells, the absence of P53 acetylation (Figure 1(c))
is consistent with selective P53-independent induction of
CDKN1A by HDACi [18]. Indeed, similar LBH589-respon-
siveness, growth arrest, and differentiation phenotypes in
the P53-null Saos-2 and MG-63 human osteosarcoma cells
(Supplementary Figure 1) strongly suggest that at least at low-
dose LBH589 acts through P53-independent mechanisms.
Consistent with 15 nM LBH589 being a sublethal concen-
tration based on the absence of morphological cell apoptotic
features, no detectable loss of cell number, and similar
proportion of early apoptotic cells toDMSOcontrol following
48 hours culture, our gene expression data demonstrated
increased expression of antiapoptotic genes (BIRC3, BCL2L2,
and CFLAR) and decreased expression of proapoptotic genes
(CASP3, BCL2L11, CARD8, CASP6, BNIP1, BCLAF1, CASP2,
and APAF1) following LBH589 treatment (Figure 3).
3.6. LBH589 Reduces Osteosarcoma Tumour Growth In Vivo.
To investigate the therapeutic potential of LBH589 on osteo-
sarcoma in vivo, 1 × 106U2OS cells were injected into the
flanks of Nude mice. We observed 100% engraftment of cells
with a tumour volume of ∼150mm3 reached 2-3 weeks after
inoculation.Micewere initially randomized to receive vehicle
control or 10mg/kg LBH589 daily by intraperitoneal injection
[19]. Maximum tolerated dose of LBH589 is 15mg/kg qd
based on a 15% of body weight loss at 10–14 days (Novartis,
personal communication). Tumours in mice treated with
vehicle control grew rapidly and reached endpoint size
within 5-6 days following the commencement of treatment
(Figures 4(a) and 4(b)). In contrast, tumours in mice
treated with 10mg/kg LBH589 were significantly smaller and
demonstrated minimal growth over a 7-day treatment period
(Figures 4(a) and 4(b)). After 5–7 days of treatment, the
body weight of mice receiving 10mg/kg LBH589 decreased
by ≥10%, and the experiment was terminated due to LBH589
dose intolerance and ethical endpoints (Figure 4(c)). This is
consistent with a previous study using human gastrointesti-
nal stromal tumour xenografts that reported dose-limiting
toxicities including 21% of body weight loss, skin dehydra-
tion, diarrhea, and histopathological changes in the spleen
and small bowel following 12 days of continuous treatment
with 10mg/kg LBH589 [19]. To determine if LBH589 could
also drive osteoblast differentiation of osteosarcoma cells in
vivo, quantitative real-time PCR was performed on tumour
tissue collected following 6 days of treatment with 10mg/kg
LBH589. Consistent with the in vitro cell culture findings, we
observed increased expression of osteoblast-specific differ-
entiation markers, including the preosteoblast marker ALPL
(3.4 fold ± 1.9, 𝑃 < 0.05) and mature osteoblast marker
SPP1 (4.9 fold ± 1.7, 𝑃 < 0.05) indicating a differentiation
phenotype (Figure 4(d)).
To improve LBH589 tolerance in vivo, we explored the
outcome of lower LBH589 doses on tumour growth. Remark-
ably, 2mg/kg and 5mg/kg, representing a fifth and a half
of the original LBH589 dose, respectively, did not result in
any detectable adverse side effects despite a tumour response
identical to the higher dose (Figures 4(b) and 4(c)).
4. Discussion
Despite the use of adjuvant chemotherapy, the prognosis
for osteosarcoma patients with metastatic and/or recurrent
disease remains poor, highlighting the urgent need for new
and improved therapies. HDACis are an emerging class of
anticancer agents with high activity in hematological malig-
nancies. However, the underwhelming effect on solid malig-
nancies and significant adverse side effects associated with
doses required to elicit a desired cytotoxic effect have limited
their applications. Here, we have identified that sub-lethal,
low-dose LBH589 acts as a potent inducer of osteosarcoma
cell differentiation. Culture of human osteosarcoma cell lines
with low-dose LBH589 inhibits cell growth and clonogenicity,
induces cell cycle arrest and senescence, and results in ter-
minal differentiation into mature, bone forming, osteoblasts.
LBH589 treatment of a mouse xenograft model of osteosar-
coma resulted in a significant inhibition of tumour growth
and increased the expression of osteoblast differentiation
markers. Titration of the LBH589 dose demonstrated a
similar tumour response in the absence of any detectable sign
of toxicity.
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Figure 3: Low-dose LBH589 treatment induces cell cycle arrest and senescence. Heatmap representation of differentially expressed genes
enriched in functional groups associated with (a) cell cycle regulation, (b) senescence-associated secretory phenotype, and (c) apoptosis.
Each column represents a distinct sample.
4.1. Osteosarcoma Results from Abnormal Differentiation.
Abnormal cellular differentiation is a characteristic of nearly
all cancers, including osteosarcoma. It is proposed that two
key transition points exist in normal osteoblast differentiation
that are the focus of oncogenic events: (1) transition from
the mesenchymal stem cell (MSC) to a osteoblast-restricted
progenitor; (2) termination of osteoblast lineage expansion
and progression of terminal differentiation [20]. Evidence
exists to support both scenarios. First, consistent with our
findings, osteosarcomas have the capacity for multilineage
differentiation along mesenchymal lines. Second, osteosar-
coma frequently exhibits expression of early osteogenic dif-
ferentiation markers such as RUNX2 and OSX1 but not ter-
minal differentiation markers, osteocalcin and osteopontin
[1]. Third, genetic mouse models in which Trp53 and Rb
are conditionally mutated through targeted deletion under
the control of the Osx1 promoter develop osteosarcoma [21].
Since Osx1 is a master regulator of preosteoblast lineage
commitment, these experiments demonstrate that the osteo-
progenitor lineage is competent to support tumor initiation.
Regardless of the precise inflection point, greater than 80%
of osteosarcomas are histopathologically graded as “poorly
differentiated,” a feature associated with a 10–15% decrease
in 5-year survival [20]. The ability of osteosarcoma cells to
retain an undifferentiated phenotype permits uncontrolled
proliferation and resistance of apoptosis. For these reasons,
targeting differentiation defects in osteosarcomapresent as an
attractive therapeutic option. Indeed, a number of transcrip-
tion factors, growth factors, and nuclear receptor agonists
have been studied in the context of differentiating-promoting
agents in osteosarcoma, but their nonspecificity and/or
inability to pharmacologically target has failed to lead to
translational outcomes (reviewed in [1]).
4.2. Epigenetic Regulation of Osteoblast Differentiation.
Increasing evidence suggests the mechanisms underlying
abnormal differentiation in osteosarcoma may be epigenet-
ically regulated. During osteoblast development, acetylation
of histones H3 and H4 increases accessibility of Runx2
to osteogenic promoter regions, including osteocalcin [22].
Further, Runx2 itself is directly suppressed by HDAC4, and
absence of HDAC4 results in transcriptional activation and
increased ossification [23]. Similarly, decreased methylation
of the osteopontin promoter is associated with an increased
expression and osteogenic differentiation [24].More recently,
in a landmark study, Kansara et al. identified several potential
tumour suppressor genes to be epigenetically silenced in
osteosarcoma [15]. Notably,WIF1 is a known regulator of the
WNTsignaling pathway and critical coordinator of osteoblast
proliferation and differentiation [15]. Together, these studies
provide compelling data implicating epigenetic regulation in
normal and abnormal osteoblast differentiation contributing
to osteosarcoma.
4.3. HDACi in Osteosarcoma. HDACis have previously been
proposed for osteosarcoma based on their ability to inhibit
human and canine osteosarcoma cell growth by inducing
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Figure 4: LBH589 reduces osteosarcoma tumour growth and drives osteoblast differentiation in vivo. (a) U2OS xenograft flank tumours
treated with vehicle control or 10mg/kg LBH589 i.p. daily for 6 days. Bar = 5mm. (b) Tumour volume. Mean ± SEM. (c) Percentage body
weight. Mean ± SEM. (d) Quantitative real-time PCR of U2OS xenograft tumours following 6 consecutive days of treatment with vehicle
control for expression of osteoblast differentiation markers. ∗𝑃 < 0.05.
apoptosis, primarily through Fas-mediated or caspase-de-
pendent mechanisms [25–28]. Here, using sublethal concen-
trations of LBH589, we have identified what we believe to be a
novel function of HDACi in inhibiting osteosarcoma growth
via regulation of tumour cell differentiation. Interestingly,
valproic acid and sodium butyrate promote preferential
osteogenic differentiation of human mesenchymal stem cells
[29]. Considering the pathogenic features of osteosarcoma
discussed above, it is tempting to speculate that this disease is
particularly sensitive to epigenetic-driven differentiation.
5. Conclusion
Thedifferentiating potential ofHDACiwas initially described
in murine erthyroluekemia cells in 1975 [11, 12]. More
recently, the ability of suberoylanilide hydroxamic acid
(SAHA/vorinostat) and trichostatin A to induce mammary
gland differentiation of human breast cancer cells suggests
that solid tumours are also susceptible to HDACi-dependent
differentiation [17, 30]. Despite these findings, this potential
mechanism of function and therapeutic strategy for HDACi
has been largely ignored in the cancer setting in favor of
cytotoxic outcomes. However, the clinical advancement of
HDACi in solid tumours has been impeded by poor tumour
response, in terms of regression and associated adverse side-
effects [13]. Here, we have reported that low-dose LBH589
inhibits osteosarcoma cell growth by driving tumor cell dif-
ferentiation, rather than death. While the precise mechanism
by which HDACi is able to promote differentiation at low-
dose and apoptosis and high-dose remains to be determined,
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we propose that low-dose LBH589 acts predominantly as a
potent “differentiating” agent. Consequently, LBH589 may
provide an effective and well-tolerated therapeutic option for
the treatment of osteosarcoma and likely other solid tumours,
particularly with an undifferentiated phenotype.
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgments
The work was supported by the Australasian Sarcoma Study
Group Andrew Ursini Sarcoma Research Grant (JEC), Vic-
torian Cancer Agency (VCA) Early Career Seed Grant
(JEC), VCA Translational Grant (DMT and DNW), and the
Victorian Government’s Operational Infrastructure Support
Program. The authors thank Novartis for the supplying of
LDE225 and thank Professor Ricky Johnstone and Professor
BryanWilliams for the helpful discussions and critical review
of the paper.
References
[1] H. H. Luu, E. R. Wagner, G. Luther et al., “Defective osteogenic
differentiation in the development of osteosarcoma,” Sarcoma,
vol. 2011, Article ID 325238, 12 pages, 2011.
[2] H.D. Dorfman and B. Czerniak, “Bone cancers,”Cancer, vol. 75,
no. 1, supplement, pp. 203–210, 1995.
[3] S. B. Lansky, J. L. Black, and N. U. Cairns, “Childhood cancer.
Medical costs,” Cancer, vol. 52, no. 4, pp. 762–766, 1983.
[4] M. P. Link, A. M. Goorin, and A. W. Miser, “The effect of
adjuvant chemotherapy on relapse-free survival in patients with
osteosarcoma of the extremity,” The New England Journal of
Medicine, vol. 314, no. 25, pp. 1600–1606, 1986.
[5] A. Longhi, C. Errani, M. De Paolis, M. Mercuri, and G. Bacci,
“Primary bone osteosarcoma in the pediatric age: state of the
art,”Cancer Treatment Reviews, vol. 32, no. 6, pp. 423–436, 2006.
[6] M. Kansara and D. M. Thomas, “Molecular pathogenesis of
osteosarcoma,” DNA and Cell Biology, vol. 26, no. 1, pp. 1–18,
2007.
[7] P. A. Meyers, G. Heller, and J. Healey, “Retrospective review of
neoadjuvant chemotheraphy for osteogenic sarcoma,” Journal of
the National Cancer Institute, vol. 84, no. 3, pp. 202–204, 1992.
[8] A. A. Sandberg and J. A. Bridge, “Updates on the cytogenetics
andmolecular genetics of bone and soft tissue tumors: osteosar-
coma and related tumors,” Cancer Genetics and Cytogenetics,
vol. 145, no. 1, pp. 1–30, 2003.
[9] S. L. Berger, T. Kouzarides, R. Shiekhattar, and A. Shilatifard,
“An operational definition of epigenetics,” Genes and Develop-
ment, vol. 23, no. 7, pp. 781–783, 2009.
[10] X. Ma, H. H. Ezzeldin, and R. B. Diasio, “Histone deacetylase
inhibitors: current status and overview of recent clinical trials,”
Drugs, vol. 69, no. 14, pp. 1911–1934, 2009.
[11] A. Leder and P. Leder, “Butyric acid, a potent inducer of ery-
throid differentiation in cultured erythroleukemic cells,” Cell,
vol. 5, no. 3, pp. 319–322, 1975.
[12] A. Leder, S. Orkin, and P. Leder, “Differentiation of ery-
throleukemic cells in the presence of inhibitors of DNA syn-
thesis,” Science, vol. 190, no. 4217, pp. 893–894, 1975.
[13] J. M.Wagner, B. Hackanson,M. Lu¨bbert, andM. Jung, “Histone
deacetylase (HDAC) inhibitors in recent clinical trials for
cancer therapy,” Clinical Epigenetics, vol. 1, no. 3-4, pp. 117–136,
2010.
[14] S. M. Taylor and P. A. Jones, “Multiple new phenotypes induced
in 10T 1/2 and 3T3 cells treated with 5-azacytidine,” Cell, vol. 17,
no. 4, pp. 771–779, 1979.
[15] M. Kansara, M. Tsang, L. Kodjabachian et al., “Wnt inhibitory
factor 1 is epigenetically silenced in human osteosarcoma, and
targeted disruption accelerates osteosarcomagenesis in mice,”
Journal of Clinical Investigation, vol. 119, no. 4, pp. 837–851, 2009.
[16] Y. Benjamini and Y. H. Y, “Controlling the false discovery rate—
a practical and powerful approach to multiple testing,” Journal
of the Royal Statistical Society B, vol. 57, no. 1, pp. 289–300, 1995.
[17] P. N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P. A.
Marks, and V. M. Richon, “The histone deacetylase inhibitor
suberoylanilide hydroxamic acid induces differentiation of
human breast cancer cells,” Cancer Research, vol. 61, no. 23, pp.
8492–8497, 2001.
[18] V. M. Richon, T. W. Sandhoff, R. A. Rifkind, and P. A. Marks,
“Histone deacetylase inhibitor selectively induces p21WAF1
expressjon and gene-associated histone acetylation,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 97, no. 18, pp. 10014–10019, 2000.
[19] G. Floris, M. Debiec-Rychter, R. Sciot et al., “High efficacy of
panobinostat towards human gastrointestinal stromal tumors in
a xenograft mouse model,” Clinical Cancer Research, vol. 15, no.
12, pp. 4066–4076, 2009.
[20] D. Thomas and M. Kansara, “Epigenetic modifications in
osteogenic differentiation and transformation,” Journal of Cel-
lular Biochemistry, vol. 98, no. 4, pp. 757–769, 2006.
[21] C. R. Walkley, R. Qudsi, V. G. Sankaran et al., “Conditional
mouse osteosarcoma, dependent on p53 loss and potentiated by
loss of Rb, mimics the human disease,” Genes and Development,
vol. 22, no. 12, pp. 1662–1676, 2008.
[22] J. Shen, H. Hovhannisyan, J. B. Lian et al., “Transcriptional
induction of the osteocalcin gene during osteoblast differenti-
ation involves acetylation of histones H3 and H4,” Molecular
Endocrinology, vol. 17, no. 4, pp. 743–756, 2003.
[23] R. B. Vega, K. Matsuda, J. Oh et al., “Histone deacetylase 4 con-
trols chondrocyte hypertrophy during skeletogenesis,” Cell, vol.
119, no. 4, pp. 555–566, 2004.
[24] E. J. Arnsdorf, P. Tummala, A. B. Castillo, F. Zhang, and C.
R. Jacobs, “The epigenetic mechanism of mechanically induced
osteogenic differentiation,” Journal of Biomechanics, vol. 43, no.
15, pp. 2881–2886, 2010.
[25] D. D. Cheng, Q. C. Yang, Z. C. Zhang, C. X. Yang, and Y. W.
Liu, “Antitumor activity of histone deacetylase inhibitor A in
osteosarcoma cells,” Asian Pacific Journal of Cancer Prevention,
vol. 13, no. 4, pp. 1395–1399, 2012.
[26] T. Imai, S. Adachi, K. Nishijo et al., “FR901228 induces tumor
regression associated with induction of Fas ligand and activa-
tion of Fas signaling in human osteosarcoma cells,” Oncogene,
vol. 22, no. 58, pp. 9231–9242, 2003.
[27] V.Thayanithy, C. Park, A. L. Sarver et al., “Combinatorial treat-
ment of DNA and chromatin-modifying drugs cause cell death
in human and canine osteosarcoma cell lines,” PLoS One, vol. 7,
no. 9, Article ID 43720, 2012.
[28] L. A. Wittenburg, L. Bisson, B. J. Rose, C. Korch, and D. H.
Thamm, “The histone deacetylase inhibitor valproic acid sensi-
tizes human and canine osteosarcoma to doxorubicin,” Cancer
Chemotherapy and Pharmacology, vol. 67, no. 1, pp. 83–92, 2011.
Sarcoma 11
[29] S. Lee, J. R. Park,M. S. Seo et al., “Histone deacetylase inhibitors
decrease proliferation potential andmultilineage differentiation
capability of humanmesenchymal stem cells,”Cell Proliferation,
vol. 42, no. 6, pp. 711–720, 2009.
[30] D. M. Vigushin, S. Ali, P. E. Pace et al., “Trichostatin A is
a histone deacetylase inhibitor with potent antitumor activity
against breast cancer in vivo,” Clinical Cancer Research, vol. 7,
no. 4, pp. 971–976, 2001.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Mediators
inflaMMation
of
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Computational and 
Mathematical Methods 
in Medicine
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Oncology
Journal of
Volume 2013
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oxidative Medicine and 
Cellular Longevity
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
